Investing.com -- Novo Nordisk raised its full-year 2026 sales and operating profit outlook on Wednesday after stronger-than-expected third-quarter performance, driven by demand for its obesity treatments, although impairment charges pushed reported operating profit lower. Still guessing which stocks will beat the market? Our AI portfolio updates monthly and is outperforming the S&P 500 by 118%. See this month's list » The Danish drugmaker now expects adjusted sales and adjusted operating profit to grow between 2% and decline 2% in 2026 at constant exchange rates, compared with its previous forecast of declines of 6% to 0% for both measures. Total obesity care sales rose 22% at constant exchange rates to 26.15 billion Danish kroner from 21.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.